Sheldon Sloan
Chief Medical Officer at Spyre Therapeutics, Inc. (SYRE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jul 2SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 6,5001,834 held (−78%) | $87.52 | $569K | -2.1% |
| Jul 2SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 1,834 | $88.34 | $162K | -3.0% |
| Jun 3SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 8,333 | $75.00 | $625K | +14.3% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 21,30657,027 held (−27%) | $69.53 | $1.5M | +23.2% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 19,65637,371 held (−34%) | $70.61 | $1.4M | +21.4% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 8,77728,594 held (−23%) | $71.56 | $628K | +19.7% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 12,77715,817 held (−45%) | $72.94 | $932K | +17.5% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 10,3585,459 held (−65%) | $73.74 | $764K | +16.2% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 5,059400 held (−93%) | $74.60 | $377K | +14.9% |
| May 1SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 400 | $75.37 | $30K | +13.7% |
| Apr 3SEC | SYRESpyre Therapeutics, Inc. | Sell Plan | 7,958 | $50.00 | $398K | +71.4% |
- Sell
Chief Medical Officer Sheldon Sloan sold $569K of SYRE at $87.52 — cuts the stake by 78%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Sheldon Sloan sold $162K of SYRE at $88.34 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Sheldon Sloan sold $625K of SYRE at $75.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Sheldon Sloan sold $1.5M of SYRE at $69.53 — cuts the stake by 27%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Sheldon Sloan sold $1.4M of SYRE at $70.61 — cuts the stake by 34%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Sheldon Sloan sold $628K of SYRE at $71.56 — pre-scheduled 10b5-1 plan sale.